CIA
ADVM

Capital Impact Advisors’s Adverum Biotechnologies ADVM Stock Holding History

Capital Impact Advisors’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-923
Closed -$76K – 253
2015
Q3 		$76K Hold
923
– – 0.04% 256
2015
Q2 		$150K Hold
923
– – 0.07% 258
2015
Q1 		$374K Buy
+923
New +$390K 0.17% 219

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital Impact Advisors's ADVM Position: Q4 2015 in Review

Capital Impact Advisors sold out of Adverum Biotechnologies (ADVM) in Q4 2015, closing a stake of 923 shares — an estimated $76K sold.

Capital Impact Advisors first reported a position in ADVM in Q1 2015 and held it in 3 quarters. The position peaked at $374K in Q1 2015. 76 funds tracked by Wall St. Rank hold ADVM as of Q4 2015.

  • Capital Impact Advisors reported no remaining Adverum Biotechnologies position as of Q4 2015 after selling out during the quarter.
  • Capital Impact Advisors sold 923 Adverum Biotechnologies shares in Q4 2015, an estimated $76K.
  • Capital Impact Advisors first reported a position in Adverum Biotechnologies in Q1 2015 and held it in 3 quarters.
  • Capital Impact Advisors's Adverum Biotechnologies position peaked at $374K in Q1 2015.
  • 76 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2015.

Based on Capital Impact Advisors's 13F filing for Q4 2015, filed 11 Jan 2016.